BETHLEHEM, Pa., July 12, 2011 /PRNewswire/ -- Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, and Absorption Systems, a leading provider of pre-clinical pharmacokinetic services, announced today that the two companies are working together to provide their clients with enhanced drug development services by integrating pre-clinical pharmacokinetic data into the dosage form development scheme.
According to Robert Lee, Ph.D., Particle Sciences' Vice President Pharmaceutical Development, "Particle Sciences has always had a methodical approach to drug product development. Dosage form design is best done when informed by the in vivo solubility, permeability and metabolism of the drug. This is true for oral drug products as well as other routes of administration. Absorption Systems has put in place a scaled in vitro / ex vivo / in vivo approach to obtaining this data, which lends itself to our needs. For those clients that desire it, Particle Sciences can integrate this data stream into our drug product development plan. Ultimately, this should prove to be a cost-effective way to drive efficiency and minimize time to the clinic."
Chris Bode, Ph.D., Vice President Scientific & Corporate Communications at Absorption Systems, adds that "Our portfolio includes a number of physicochemical and biological tests that can make formulation development a more rational and efficient process. Particle Sciences is a leader in drug formulation and manufacturing, and we are very pleased that they are leveraging our toolset in their efforts. I believe this is consistent with their overall innovative and comprehensive approach to drug product development".
Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in